LifeArc awards £3 million to advance promising early rare disease research from the lab to the patient

Pump-prime funding to help researchers get innovative approaches off the ground

LifeArc Ventures invests in Maxion Therapeutics

Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases

Celebrating the International Day of Women and Girls in Science

LifeArc celebrates this year's UN Day for Women and Girls in STEM.

LifeArc Ventures – strong performance in 2022 & sustained investment in innovation

LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, provides an update on its portfolio.

£1 million awarded to develop cutting-edge therapies for motor neuron disease

LifeArc, Motor Neurone Disease Association and My Name’5 Doddie Foundation jointly award £1 million to progress development…

LifeArc portfolio company RQ Bio’s antibody enters clinical trials

The first of RQ Bio's discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients has entered clinical trials.

Alzheimer’s drug lecanemab approved by US regulator

LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.

Evolving our science to solve complex healthcare challenges

Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.

2022 wrapped – our highlights from a pivotal year

We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.